Wegovy Pill UK: Cost, Approval & When to Expect It

Medically reviewed as of 22nd June 2026

‍

Googling ‘Wegovy pill UK’ at 11 pm? We understand, and you’re not alone. It’s all over social media, especially if you follow influencers from the US.

It is a pill version of semaglutide, the same molecule that’s in the Wegovy injection. It originally launched in the United States in January 2026.

The question everyone in the UK is asking is: when do we get ours?

Good news! It has now been approved by the MHRA in the UK as of the 12th July 2026!

Here’s the full picture on what’s happening with the approval, what we know about cost, who might be eligible, and what you can actually do right now if you’re ready to start.

‍

Is the Wegovy Pill Approved in the UK Yet?

Yes.

How Much Will the Wegovy Pill Cost in the UK?

Pricing varies by competitor and the dosage. We've seen pricing range from £144 to £244 whilst SheMed prices starts from £69 per month (on a 12 month commitment)

Oral vs Injectable Wegovy: Expected Cost Difference

Injectable Wegovy currently costs £130–£295/month privately in the UK, depending on dose. Most analysts, including us, expect the pill to be priced below the injection. Here’s why:

•       The pill doesn’t require refrigeration. So, no cold chain storage and distribution costs

•       Manufacturing a tablet is usually less complex than producing a pre-filled injectable pen

•       Novo Nordisk has signalled that the pill is partly designed to improve accessibility

 ‍

Will the Wegovy Pill Be Available on the NHS?

Not any time soon. Here are the steps that need to happen before the Wegovy pill is given access to the NHS:

For context, even the injectable version of Wegovy, which has been approved in the UK since 2022, is still only available through specialist NHS weight management services with long waiting lists in most areas. You can expect the same journey for the pill.

So, if you’re waiting for the NHS to prescribe the Wegovy pill, you could be waiting a while.

And if that’s the case, the next question naturally would be -

Will buying the Wegovy pill privately make sense?

When comparing, it’ll be unfair to only look at the medication price. A good private programme can offer you much more than just a prescription. Things that are important for your smooth journey and safe transformation. They include -

•       Clinical assessment before prescribing

•       Blood tests (thyroid function, liver, HbA1c, cholesterol)

•       Ongoing clinician-led dose reviews

•       Side effect support and an accessible clinical team

•       Repeat blood monitoring at 6 and 12 months

Where to Get the Wegovy Pill in the UK?

The route should be the same for the pill as it was for the injection.

•       Private online clinics - The fastest route. Online providers like SheMed that are GPhC-registered and CQC-regulated will likely offer the pill shortly after MHRA approval, following the same clinical assessment process as the injection

•       High street pharmacies with prescribing services: Boots, Lloyds Pharmacy, and others already offer injectable GLP-1s via online consultation. The pill would likely be added similarly

•       NHS GP: Once NICE guidance is in place, which will be much later than private availability. It will also be subject to local commissioning decisions

•       NHS specialist services: This will be the last route to open up, and the most restricted in terms of eligibility

NICE Eligibility Criteria: What the Current Framework Looks Like

This is what the eligibility works in the UK for injectable Wegovy and Mounjaro -

•       Private prescription: BMI 30+ (or BMI 27+ with at least one weight-related condition such as type 2 diabetes, hypertension, dyslipidaemia, or obstructive sleep apnoea)

•       NHS via specialist services (NICE TA875): BMI 35+ with at least one comorbidity, referred to a specialist weight management service

•       NHS GP prescribing (expected in 2026–27): BMI 35–39.9 with weight-related comorbidities, with eligibility widening over the coming years

The pill will almost certainly follow the same framework. It’s basically the same drug, with the same clinical evidence base. So, Novo Nordisk will naturally seek the same indications.

Specific Considerations for Women: PMOS, Menopause, and Thyroid Medication

This is the part that we feel is the most important.

PMOS:

GLP-1 medications are not licensed specifically for PMOS (formally known as Polycystic Ovarian Syndrome or PCOS for short) in the UK, but if you suffer from PMOS and also meet the BMI criteria, you can get them prescribed for weight management.

Weight loss is known to significantly improve PMOS symptoms like cycle regularity, androgen levels, and insulin sensitivity. If you have PMOS and a BMI of 27+ with metabolic comorbidities, there’s a high chance you meet the private eligibility criteria right now.

Perimenopause and menopause:

Weight gain around perimenopause is common. And this is the kind of gain that doesn’t really go away despite a diet and regular exercise because of its hormonal nature that affects metabolism and fat distribution.

Post-hoc analyses from OASIS 4 specifically looked at menopausal status and found that women across all stages, pre-, peri-, and post-menopausal, lost 15–18% of body weight on average.

The pill, just like the injection, works on the biology rather than just behaviour.

Thyroid:

If you’re taking levothyroxine (thyroid medication), you might need to plan it properly. The Wegovy pill requires a strict 30-minute fast, and levothyroxine also requires an empty stomach. So you’ll just have to plan both accordingly. But don’t worry. Your prescriber will help you work this out. Just make sure you disclose all medications during your clinical assessment.

What about Switching From Injectable Wegovy or Mounjaro?

If you’re already on the injection and want to switch to the pill, you will need a new clinical assessment. But that doesn’t mean starting from scratch again. It’s just about disclosing all details about your current treatment to your prescriber.

The most important thing to know here is: switching from the injection to the pill is not a direct dose-for-dose swap. The pill has a higher rate of nausea and vomiting during the early weeks. Your prescriber will need to determine an appropriate oral starting dose.

‍

‍

‍

Injectable Wegovy – Your answer

Wegovy injection is fully licensed in the UK for weight management and is available privately starting from just £59. It contains the same active ingredient, semaglutide and works on the same GLP-1 mechanism.

The trial results show 14.9% weight loss at the 2.4mg dose (STEP 1), and 20.7% with the newly approved 7.2mg dose (STEP UP, MHRA approved January 2026).

If you have a genuine needle phobia, then we understand the wait. But, if it’s something else, like the convenience, the no-fridge appeal, or simply just curiosity about the new format, starting with the injection now and switching to the pill later might not be the worst idea.

Mounjaro: Another good option

If you think Wegovy’s results are not appealing enough, you can try the double-action Mounjaro. It contains the active ingredient tirzepatide and works on both GLP-1 and GIP. It is currently the highest-performing licensed weight loss medication in the UK. It produces an average of 22.5% weight loss at 72 weeks at the 15mg dose (SURMOUNT-1).

Want to further understand the difference between Wegovy and Mounjaro?

We’ve written an entire article on Wegovy and Mounjaro, check it out.

Frequently Asked Questions

When will the Wegovy pill be available in the UK?

It's now available in the UK as of June 12th 2026! NHS access would take longer, most probably in 2027, after the NICE review.

How much does the Wegovy pill cost?

Prices can vary depending on who which provider you choose. Prices in the market can range from £144 up to £244 depending on the dosage. The SheMed Wegovy Pill is now available from just £59 per month (limited time price drop).

Is there a pill alternative to Wegovy available today?

Rybelsus (oral semaglutide, 3–14mg) is the only oral semaglutide currently licensed in the UK, but it’s licensed for type 2 diabetes only, not weight loss. Orlistat and MySimba are one of two oral medications currently NHS-licensed for obesity, but it works differently and produces far lower average weight loss (around 3–5%). Neither is the same product as the higher-dose oral semaglutide designed for weight management.

Will the NHS prescribe the Wegovy pill?

Most likely yes, but not anytime soon. The realistic timeline is 2027, and that too only for patients meeting strict eligibility criteria.

‍

Sources & Further Reading

1. MHRA — GLP-1 Medicines for Weight Loss and Diabetes: What You Need to Know (GOV.UK, 2026)

2. MHRA — Updated Guidance for Semaglutide Prescribers and Patients (GOV.UK, February 2026)

3. NICE TA875 — Semaglutide for Weight Management

4. NICE TA1026 — Tirzepatide (Mounjaro) for Managing Overweight and Obesity

5. Wharton S et al. — OASIS 4: Oral Semaglutide 25mg. NEJM, 2025

6. SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (NEJM, 2022)

7. NHS — Obesity: Treatment Overview

8. MHRA Yellow Card — Report a Side Effect

9. GPhC — Check a Pharmacy Register

10. Source: FDA — Wegovy oral semaglutide approval (December 2025)

11.  Source: MHRA — How medicines are approved in the UK

12.  Source: MHRA — GLP-1 Medicines for Weight Loss and Diabetes (GOV.UK, updated 2026)

13. Source: Medino.com — Wegovy Cost Per Month UK (2026 Guide)

14. Source: MHRA — Wegovy 7.2mg approval (January 2026)

15: Medicines - MySimba